[Effects of biologic therapies on systemic osteoporosis in patients with rheumatoid arthritis].
Biologic therapies including tumor necrosis factor alpha (TNF-alpha)-blocking therapy have been shown to reduce disease activity measures and joint damage progression. However, effects of biologic therapies on systemic osteoporosis remain to be elucidated in patients with rheumatoid arthritis (RA). In this review article, we reviewed the literature on the issue after we described our hypothesis on the pathogenesis of synovitis in patients with RA.
Kotake
Shigeru
S
Institute of Rheumatology, Tokyo Women's Medical University.
Yago
Toru
T
Nanke
Yuki
Y
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000209:etiology*; D000069448:Denosumab; D004224:Diterpenes; D015195:Drug Design; D006801:Humans; D000069285:Infliximab; D007375:Interleukin-1 / Q000502:physiology; D020381:Interleukin-17 / Q000502:physiology; D015850:Interleukin-6 / Q000502:physiology; D010010:Osteoclasts; D010024:Osteoporosis / Q000188:drug therapy* / Q000209:etiology*; D053245:RANK Ligand / Q000276:immunology / Q000502:physiology / Q000627:therapeutic use; D019947:Receptors, Interleukin-6 / Q000276:immunology; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology / Q000502:physiology
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004224:Diterpenes; D007375:Interleukin-1; D020381:Interleukin-17; D015850:Interleukin-6; D053245:RANK Ligand; D019947:Receptors, Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D000069448:Denosumab; D000069285:Infliximab; C031049:geranylgeranylacetone